How Does Wegovy Work For Weight Loss?

Wegovy has become one of the most talked about weight loss treatments in the UK, but many people beginning to explore it are not entirely clear on how it actually works in the body. Understanding the mechanism behind the medication, what it does and what it does not do, can help set more realistic expectations and make the most of treatment from the start.

Key points you should know are:

• Wegovy is a GLP-1 receptor agonist that mimics a naturally occurring hormone
• It reduces appetite by acting on the brain’s hunger signalling pathways
• It also slows digestion, helping you feel fuller for longer after meals
• It is taken as a weekly injection and is prescription only
• Lifestyle changes remain an important part of getting the best results

If you are considering Wegovy and want to understand whether it suits your situation, contact our Airdrie team or book a consultation to find out more.

What Is Wegovy?

Wegovy is the brand name for semaglutide 2.4mg, a prescription weight loss medication approved for use in the UK. It belongs to a class of medicines known as GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, which is a hormone naturally produced in the gut after eating. Wegovy works by mimicking this hormone at a higher level than the body would naturally produce it.

It is important to distinguish Wegovy from Ozempic, which also contains semaglutide but at a lower dose approved for type 2 diabetes management rather than weight loss. Wegovy is specifically licensed for chronic weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight related health condition.

The Science Behind How Wegovy Works

GLP-1 receptors are found in several parts of the body, including the brain, the gut and the pancreas. When semaglutide activates these receptors, it triggers a series of effects that work together to support weight loss.

The primary mechanism is appetite reduction. Wegovy acts on receptors in the hypothalamus, the part of the brain responsible for hunger and satiety signalling. By activating these receptors, it reduces the intensity of hunger signals, making it easier to eat less without feeling deprived.

At the same time, Wegovy slows gastric emptying, the rate at which food moves from the stomach into the small intestine. This slowing means that even a smaller meal produces a prolonged feeling of fullness, reducing the urge to snack between meals or eat large portions.

There is also evidence that semaglutide influences food reward pathways in the brain, reducing cravings and making highly palatable foods feel less compelling. Patients often describe this as a change in their relationship with food rather than simply feeling less hungry.

How Is Wegovy Taken?

Wegovy is administered as a subcutaneous injection once weekly, using a pre-filled pen device. The injection is typically given in the stomach, thigh or upper arm and is designed to be self-administered at home once a patient has been trained how to use the pen correctly.

The medication follows a structured dose escalation schedule:

• Starting at 0.25mg weekly for the first four weeks
• Increasing to 0.5mg for the following four weeks
• Further increases at four-weekly intervals through 1mg and 1.7mg
• Reaching the maintenance dose of 2.4mg from week seventeen onward

This gradual approach is designed to give the body time to adjust at each stage, reducing the risk and severity of side effects such as nausea, which are most common during dose increases.

What Results Can You Expect From Wegovy?

Clinical trials that led to Wegovy’s approval showed meaningful average weight loss outcomes. The STEP trials, which investigated semaglutide 2.4mg in adults with obesity or overweight, showed that patients on Wegovy alongside lifestyle intervention achieved significant average weight reduction compared to those on placebo over 68 weeks. These trials were conducted across a broad population, giving regulators and clinicians confidence in the medication’s effectiveness as part of a structured weight management approach.

What the trial data also showed is that results are not uniform. Some participants lost considerably more than the average, while others lost less. This variation is normal and reflects the fact that weight management involves many individual factors beyond the medication itself. Body composition, metabolic rate, eating patterns, sleep quality and activity level all contribute to overall outcomes.

It is important to understand that individual results vary considerably. Factors including starting weight, diet, activity level, metabolic factors and consistency with treatment all influence outcomes. Wegovy does not produce the same result in every person, and results are generally stronger when the medication is supported by genuine lifestyle changes. This is not a criticism of the medication but a reflection of how complex weight management is as a process.

Common Side Effects And How They Are Managed

The most frequently reported side effects with Wegovy are gastrointestinal in nature and are most likely to occur during dose increases. These include:

• Nausea, which is the most commonly reported effect
• Vomiting
• Diarrhoea or constipation
• Stomach discomfort or bloating
• Reduced appetite beyond the intended effect

These effects tend to settle as the body adjusts at each dose stage. Eating smaller meals, avoiding high fat or very rich foods, staying hydrated and eating slowly can all help reduce their intensity. A small number of patients experience side effects that require staying on a lower dose for longer, or in rare cases, discontinuing treatment.

Who Is Wegovy Suitable For?

Wegovy is generally suitable for adults who meet the following criteria:

• BMI of 30 or above
• BMI of 27 or above alongside at least one weight related condition such as type 2 diabetes, high blood pressure or high cholesterol
• Aged 18 or over
• Not pregnant or breastfeeding
• No personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• No history of pancreatitis that would contraindicate use

A full medical assessment is required before prescribing, and your prescriber will review your medical history and current medications to confirm suitability. Wegovy is not appropriate for everyone, and the assessment exists to ensure it is safe for your individual circumstances.

How Wegovy Differs From Mounjaro

A common question is how Wegovy compares to Mounjaro, which is the other leading injectable weight loss treatment available privately in the UK. The key difference lies in the mechanism.

Wegovy works on a single hormone pathway, GLP-1 only. Mounjaro (tirzepatide) works on two separate pathways, GLP-1 and GIP, which is why it is described as a dual hormone agonist. Clinical evidence suggests that Mounjaro’s dual mechanism may produce stronger average weight loss outcomes for some patients, though individual response varies and neither medication is universally superior for every person.

The right choice between the two depends on your medical history, any relevant contraindications, your personal goals and your prescriber’s assessment.

What Happens When You Stop Taking Wegovy?

This is an important consideration that is often overlooked in early discussions about treatment. Wegovy does not produce permanent changes to appetite regulation. When the medication is stopped, the hormone signalling it produces fades, and appetite typically returns to pre-treatment levels over time. This means that weight regain is common after stopping without a maintenance plan in place.

Research following patients who discontinued semaglutide after trial periods showed that a significant proportion of weight lost during treatment was regained within a year of stopping. This does not mean treatment is pointless, but it does underline that the habits built during treatment matter as much as the medication itself.

A structured stopping or maintenance plan, including dietary habits and activity level adjustments made during treatment, gives the best chance of maintaining results after the medication is no longer being used. Some patients choose to remain on a lower maintenance dose, while others transition to lifestyle management alone once they have established consistent habits. This is something we discuss with all patients at CarePoint Pharmacy as part of the ongoing review process, so stopping is never abrupt or unplanned.

How Wegovy Fits Into A Broader Weight Management Plan

Wegovy is most effective when it is one part of a wider approach rather than the entirety of it. The appetite suppression it provides creates a window of opportunity to build sustainable habits around food, movement and routine. Patients who use this window well, building smaller meal structures, increasing activity levels and addressing emotional or habitual eating patterns, tend to have better long term outcomes than those who rely on the medication alone.

This is why access to clinical support, nutritional guidance and ongoing reviews matters so much throughout treatment. Weight management is not a single intervention but an ongoing process, and Wegovy is a tool within that process rather than a complete solution in itself. At CarePoint Pharmacy, we work with patients to make sure the wider context of their health and habits is considered at every stage.

Why Clinical Support Makes A Difference

Wegovy is a prescription medicine and should never be used without proper clinical oversight. For patients who have been wondering whether weight loss injections are available on the NHS, private prescribing through a regulated pharmacy is often the most practical and timely route. At CarePoint Pharmacy in Airdrie, the treatment journey includes:

1. An initial eligibility assessment covering medical history, current medications and relevant health markers
2. A discussion of treatment goals and realistic expectations
3. Prescription and instruction on correct self-injection technique
4. Structured dose escalation reviewed at each stage
5. Ongoing clinical reviews to assess progress and manage side effects
6. Nutritional and lifestyle guidance throughout
7. Maintenance planning as the treatment progresses

This structured support helps patients get the most from the medication while keeping safety central to every stage of the process.

Wegovy In The Context Of Overall Health, Not Just Weight

It is worth situating Wegovy within a broader understanding of what weight management means for health. Excess weight is associated with a range of conditions including type 2 diabetes, cardiovascular disease, sleep apnoea, joint problems and some cancers. Weight loss through treatment such as Wegovy can contribute to improvements in many of these conditions, not just the number on the scale.

For some patients, the most significant benefit of treatment is not cosmetic but clinical, such as improved blood sugar control, reduced blood pressure or resolution of sleep apnoea symptoms. These health improvements are part of the full value of treatment and should be part of the conversation at consultation and review rather than treated as secondary to the weight loss figure alone.

Frequently Asked Questions

Understanding how Wegovy works is the first step. The next is finding out whether it is right for you. Contact our Airdrie team or book your consultation online today.